Text Size

Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future

Levin, L .A.; Patrick, C.; Choudry, N.B.; Sharif, N.A.; Goldberg, J.L.


  • 2022
  • Front Neurol
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Departments of Ophthalmology and Visual Sciences, Neurology & Neurosurgery, McGill University, Montreal, QC, Canada. TELUS Health, Ottawa, ON, Canada; Global Alliances and External Research, Ophthalmology Innovation Center, Santen Inc., Emeryville, CA, United States; Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, United States

Related Publications

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.


Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022